[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-total-occlusion-cto\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-total-occlusion-cto":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,81,104,132,162,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100601738","optimization-of-complex-percutaneous-coronary-intervention-with-liberal-use-of-intracoronary-imaging-versus-contemporary-practice-100601738",false,"NCT07114393","Optimization of Complex Percutaneous Coronary Intervention With Liberal Use of Intracoronary Imaging Versus Contemporary Practice","OPTIMIZE-PCI 2","Inclusion Criteria:\n\n* All patients above the age of 18, included in the Netherlands Heart Registration (NHR) quality database after receiving PCI in complex coronary lesions, will be included in the analyses of this project.\n* Meeting one or more of the following complexity criteria:\n\n  * Left main: A stenosis of \\>50% and\u002For a FFR ≤ 0.80 and iFR ≤ 0.89 in the left main.\n  * Severely calcified lesion: Defined as use of calcium modification therapy (e.g. cutting balloon, scoring balloon, rotablation, orbital atherectomy, intravascular lithotripsy).\n  * Chronic total occlusion: Coronary CTO is defined as an obstruction of the coronary artery with the following classic lesion characteristics:\n\n    * TIMI flow 0\n    * Absence of contrast stasis at the site of the proximal capillaries\n    * Presence of collateral vessels\n    * Estimated occlusion duration of at least 3 months.\n  * Ostial lesion: Lesion at the origin (within 5 mm) of a major coronary vessel (LM, LAD, RCX and RCA).\n  * Long lesion: A vessel treated with one or multiple stents with a total stent length of ≥38 mm is considered a long lesion.\n  * Bifurcation (true): A coronary artery narrowing occurring adjacent to, and\u002For involving, the origin of a significant side branch ≥ 2.5mm. Only true bifurcation will be included, i.e. medina 1,1,1\u002F1,0,1\u002F0,1,1.\n  * In-stent restenosis: A reduction ≥50% of the luminal diameter within the previously stented segment or the vessel segments 5 mm proximal and distal to the stent (the \"stent edges\"), as assessed by coronary angiography.\n\nExclusion Criteria:\n\n\\- Non complex PCI","ALL","18 Years",{"count":19,"type":20},11092,"ESTIMATED","1 Year","OBSERVATIONAL","Coronary artery disease remains a leading cause of mortality worldwide and is commonly treated with percutaneous coronary intervention (PCI). Typically, PCI is guided by invasive coronary angiography (ICA). However, ICA has inherent limitations in accurately assessing vessel dimensions, calcium burden, circumferential tissue and whether a stent has achieved full expansion. Therefore ICA alone is insufficient for guiding stent optimization, especially in complex lesions which are most vulnerable to long-term stent failure. To overcome the limitations of ICA, intracoronary imaging can be used to guide and optimize PCI. The advantages of intracoronary imaging include obtaining larger lumen areas, better stent expansion and strut apposition, full lesion stent coverage and identifying stent complications. Multiple randomized studies have shown that these advantages translate into a reduction in major adverse cardiovascular events (MACE) in complex PCI. Consequently, the recommendation for intracoronary imaging has been upgraded in the most recent guidelines.\n\nDespite robust evidence supporting its benefits, intracoronary imaging remains relatively underused in real-world practice and in the Netherlands it is only used in 7% of complex PCI procedures. This underutilization may be attributed to several factors, including operator and hospital-dependent issues such as lack of experience, reluctance to spend additional time on intracoronary imaging and concerns about its cost-effectiveness. Therefore, initiating an implementation project to incorporate intracoronary imaging into routine use in the catheterization lab during complex PCI would be highly valuable. Such a project could make imaging-guided PCI the standard of care in complex PCI. Additionally, it could evaluate the cost-effectiveness of routine intracoronary imaging during complex PCI.\n\nFor this reason we designed the OPTIMIZE-PCI II, a national registry-based quality improvement project. This project is aimed at implementing a liberal intracoronary imaging-guided strategy for complex PCI across multiple centres in the Netherlands, with data extraction from the Netherlands Heart Registration (NHR) database. The objective of the OPTIMIZE-PCI II is to establish a routine use of intracoronary imaging in complex PCI, to determine if this approach reduces adverse cardiac events in real-world practice, and evaluate its cost-effectiveness.",[25,26,27,28],"Coronary Artery Disease","Coronary Artery Disease (Left Main)","Chronic Total Occlusion (CTO)","Bifurcation Coronary Artery Disease",[30,31,32,33],"percutaneous coronary intervention","intracoronary imaging","stent optimization","complex coronary artery disease","RECRUITING","2026-03-24",{"date":37,"type":38},"2026-03-27","ACTUAL",{"date":40,"type":38},"2025-04-01",{"date":42,"type":20},"2027-05-01",{"name":44,"class":45},"Cathreine BV","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100628594","clinical-outcomes-of-drug-coated-balloons-in-the-treatment-of-patients-with-coronary-de-novo-chronic-total-occlusion-lesions-100628594","NCT07463664","Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions","Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions: A Multicenter, Randomized Controlled Trial","DCB-CTO","Inclusion Criteria:\n\n* Patient voluntarily participates in the study and has provided written informed consent.\n* Presence of clinical indication for Percutaneous Coronary Intervention (PCI) of the Chronic Total Occlusion (CTO) (e.g., symptoms of angina pectoris or evidence of myocardial ischemia).\n* Target lesion is located in a de novo coronary artery.\n* Angiographically confirmed CTO (TIMI grade 0 flow), with evidence supporting an occlusion duration of ≥ 3 months.\n* Successful guidewire crossing of the target CTO lesion has been achieved during the index procedure.\n* After adequate vessel preparation: Distal TIMI grade 3 flow has been restored; Target lesion residual diameter stenosis is \\\u003C 50% (e.g., by visual estimate or QCA as per protocol); Absence of flow-limiting dissection or other complications requiring immediate stent implantation.\n* Target vessel Reference Vessel Diameter (RVD) is between 2.25 mm and 4.0 mm (inclusive, assessed by visual estimate or QCA\u002FIVUS as per protocol).\n* In the judgment of the interventional operator, the lesion is deemed suitable for treatment with both a Drug-Coated Balloon (DCB)-based strategy and a Drug-Eluting Stent (DES)-only strategy.\n* Patient is able and willing to comply with the study protocol requirements, including the specified follow-up schedule.\n* Female patients of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use an effective method of contraception throughout the study period.\n\nExclusion Criteria:\n\n* Target CTO lesion is the culprit vessel responsible for the presenting Acute Myocardial Infarction (AMI).\n* Patient is in cardiogenic shock.\n* Presence of severe heart failure (New York Heart Association \\[NYHA\\] Class IV) or Left Ventricular Ejection Fraction (LVEF) \\\u003C 30%.\n* History of stroke or Transient Ischemic Attack (TIA) within the previous 3 months.\n* Known high risk of bleeding or contraindication to Dual Antiplatelet Therapy (DAPT).\n* Presence of severe hepatic impairment and\u002For severe renal impairment (e.g., estimated Glomerular Filtration Rate \\[eGFR\\] \\\u003C 30 ml\u002Fmin\u002F1.73m² or requirement for chronic dialysis).\n* Known hypersensitivity or contraindication to required study medications (e.g., antiplatelet agents, contrast media), DCB\u002FDES drug coatings, or device materials (e.g., stent alloys, polymers).\n* Target lesion located in an unprotected left main coronary artery, a saphenous vein graft, or an arterial graft.\n* Presence of severe lesion calcification that prevents adequate vessel expansion despite attempted lesion preparation techniques (e.g., rotational atherectomy, intravascular lithotripsy).\n* Target lesion is a CTO within a previously stented segment (In-Stent Restenosis \\[ISR\\] or In-Stent Thrombosis \\[IST\\]).\n* Failed attempt at CTO recanalization during the index procedure (i.e., failure to cross the lesion with a guidewire or failure to restore TIMI grade 3 flow).\n* Occurrence of a complication after vessel preparation that necessitates immediate stent implantation (e.g., flow-limiting dissection, perforation requiring a covered stent).\n* Concurrent enrollment in another interventional clinical trial that may interfere with the study endpoints or assessments.\n* Female patient is pregnant or breastfeeding.\n* Patient judged by the investigator to be unsuitable for the study for any reason, including anticipated poor compliance with the protocol.","80 Years",{"count":57,"type":20},200,"INTERVENTIONAL",[60],"NA","The aim of this study is to evaluate the long-term efficacy and safety of drug-coated balloon (DCB) strategies, including DCB alone or hybrid strategies of DCB and drug-eluting stent (DES), compared to DES-only in patients with chronic total occlusion (CTO) after successful recanalization. Through a prospective, multicenter randomized controlled trial, we will directly compare the long-term outcomes of these two treatment strategies in CTO patients to fill the gap in existing research regarding direct comparative data between DCB and DES in CTO treatment. This study expects to provide high-quality evidence for optimizing CTO treatment, potentially improving treatment strategies in complex cases, reducing stent usage, lowering the risk of complications, and ultimately enhancing patient prognosis.",[63,27,64],"Chronic Total Occlusions of Coronary Arteries","Coronary Artery Disease (CAD)",[66,67,68,69,70],"drug-coated balloon","Coronary artery disease","chronic total occlusion","drug-eluting stent","clinical outcome","2026-03-05",{"date":73,"type":38},"2026-03-11",{"date":75,"type":38},"2025-04-28",{"date":77,"type":20},"2026-12-31",{"name":79,"class":45},"The First Affiliated Hospital of Zhengzhou University",18,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":90,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100627686","chronic-total-occlusion-and-triglyceride-glucose-index-100627686","NCT07451860","Chronic Total Occlusion and Triglyceride-Glucose Index","The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease","Inclusion Criteria:\n\n* Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI \\>30 kg\u002Fm²), inaccessible patient records",true,{"count":57,"type":20},"1 Day","We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.",[93,27,94],"CAD - Coronary Artery Disease","Triglycerid Glucose Index","NOT_YET_RECRUITING","2026-02-28",{"date":71,"type":38},{"date":99,"type":20},"2026-03-15",{"date":101,"type":20},"2026-09-15",{"name":103,"class":45},"Kırıkkale University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100586592","trio-cto-taiwan-research-initiative-on-coronary-total-occlusion-100586592","NCT06917378","TRIO CTO (Taiwan Research Initiative on Coronary Total Occlusion)","The Multicenter Study to Evaluate Clinical and Angiographic Factors in Patients With Coronary Artery Chronic Total Occlusion in Taiwan","Inclusion criteria\n\n1. Over 20 years old\n2. Chronic total occlusion confirmed by coronary angiography, and noted for more than 3 months\n\nExclusion criteria Nil","20 Years","120 Years",{"count":114,"type":20},5000,"Coronary chronic total occlusions (CTO) present a significant challenge in the field of interventional cardiology. These complex lesions, characterized by complete blockage of a coronary artery for a prolonged duration, often require specialized techniques and strategies to achieve successful revascularization.",[27],[118,119,67,120,121],"CTO","Coronary Chronic Total Occlusion","Coronary intervention","Collateral channel","2025-12-10",{"date":124,"type":38},"2025-12-18",{"date":126,"type":38},"2017-01-01",{"date":128,"type":20},"2034-12-31",{"name":130,"class":45},"National Taiwan University Hospital",3,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":46},"100594546","fapi-imaging-predicts-adverse-cardiac-events-in-chronic-total-occlusion-100594546","NCT07020858","FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion","The Value of FAPI Imaging for the Prediction of Adverse Cardiovascular Events in Chronic Total Occlusion of Coronary Artery Disease (FACT-2 Trial)","FACT-2","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of ≥1 untreated chronic total occlusion (CTO):Defined as complete occlusion of a major coronary artery or relevant collateral (reference vessel diameter ≥2.5 mm or confirmed by two independent interventional cardiologists), with TIMI flow grade 0 in the distal segment and duration ≥3 months.Preoperatively confirmed by coronary angiography or coronary computed tomography angiography (CTCA).\n3. Willingness to undergo FAPI-PET imaging and receive PCI under imaging guidance.\n4. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to antiplatelet therapy: Allergy or intolerance to aspirin, clopidogrel, or ticagrelor.\n2. Severe liver dysfunction: Liver function parameters exceeding 3× the upper limit of normal.\n3. Severe chronic kidney disease: Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n4. Life expectancy \\\u003C1 year due to non-cardiovascular comorbidities.\n5. Pregnancy or women of childbearing potential (unless surgically sterile or using contraception).",{"count":141,"type":20},470,"2 Years","Prospective, observational, single-center cohort study\n\nHypothesis Higher myocardial FAPI uptake in CTO patients predicts a greater incidence of major adverse cardiovascular events (MACE) within 12 months after PCI. FAPI PET\u002FCT imaging is associated with plaque vulnerability features and may serve as a non-invasive marker for fibrotic activity and adverse cardiac remodeling.\n\nInclusion Criteria\n\n* Age ≥ 18 years\n* Presence of at least one untreated chronic total occlusion (CTO) lesion in a major coronary artery (diameter ≥ 2.5 mm, TIMI 0 flow for ≥ 3 months) confirmed by coronary angiography or CTCA\n* Patient eligible for PCI and undergoing FAPI PET\u002FCT imaging prior to intervention\n* Written informed consent provided\n\nExclusion Criteria\n\n* Allergy or contraindication to antiplatelet agents (aspirin, clopidogrel, or ticagrelor)\n* Severe liver dysfunction (liver enzymes \\>3× upper limit of normal)\n* Severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Estimated life expectancy \\\u003C 1 year\n* Pregnancy or potential for pregnancy\n\nPrimary Endpoint Incidence of 1-year MACE, defined as a composite of: Cardiac death, Myocardial infarction, Stroke, Urgent revascularization\n\nSecondary Endpoints\n\n* All-Cause Mortality\n* Death from any cause within 12 months\n* Quality of Life Change: Measured by Seattle Angina Questionnaire (SAQ): changes in angina frequency, physical limitation, and treatment satisfaction\n* Repeat PCI Events: Incidence of: In-stent restenosis (ISR): ≥50% luminal loss in previously stented segment; Target lesion revascularization (TLR): at original PCI lesion; Target vessel revascularization (TVR): other sites in same vessel; De novo lesions: new lesions not previously treated\n\nSample Size Estimated 470 patients\n\nFollow-Up Duration 12 months post-PCI, One follow-up visit including clinical exam, SAQ questionnaire, imaging (PET\u002FCT, echocardiography), and laboratory testing.",[27,145],"Chronic Coronary Syndrome",[147,148,149,150,151,152],"Coronary Heart Disease","Major adverse cardiovascular events (MACE)","Plaque vulnerability","Optical coherence tomography (OCT)","Fibroblast activation protein inhibitor (FAPI)","Percutaneous coronary intervention (PCI)","2025-06-16",{"date":155,"type":38},"2025-06-19",{"date":157,"type":38},"2025-04-15",{"date":159,"type":20},"2027-03-15",{"name":161,"class":45},"Lin Zhao",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":142,"studyType":22,"phases":4,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100566495","fapi-imaging-assessment-of-chronic-total-occlusion-100566495","NCT06655922","FAPI Imaging Assessment of Chronic Total Occlusion","The Clinical Value of FAPI Imaging in Assessing Chronic Total Occlusion Lesions in Patients with Coronary Heart Disease (FACT Trial)","FACT","Inclusion Criteria:\n\n* Age \\> 18 years\n* Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches \\[reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists\\], with TIMI 0 in the distal segment and at least 3 months old\n* Patient has a clinical indication to perform CTO PCI\n* Willing to participate and able to understand, read and sign the informed consent document.\n\nExclusion Criteria:\n\n* Hypersensitivity to aspirin, clopidogrel, or -limus families \u002F or contraindication to antiplatelet agents\n* Severe hepatic dysfunction (≥3 times normal reference values)\n* Severe chronic kidney disease (estimated Glomerular Filtration Rate \\[eGFR\\] \\<30 mL\u002Fmin\u002F1.73m2)\n* Life expectancy \\< 1 years\n* Pregnant women or women with potential childbearing",{"count":171,"type":20},167,"This registry will include consecutive patients presenting with at least one chronic total coronary occlusion (CTO) identified via coronary angiography or cardiac computed tomography angiography (CCTA) at our center. Due to the complexity of CTO lesions, both procedural success rates and prognosis improvements are limited. The progression and development of atherosclerotic plaques involve fibroblast activity, contributing to the formation of fibrous caps and calcified nodules through various mechanisms. Myocardial fibrosis within chronically occluded segments is strongly linked to ventricular remodeling and patient prognosis. The activation of cardiac fibroblasts (CFs) is a critical early phase in myocardial fibrosis, playing a key role in fibrotic progression. However, the role of activated CFs in CTO patients has remained unclear, mainly due to the lack of reliable in vivo assessment techniques for detecting CF activation.\n\nRecent studies have demonstrated that radionuclide-labeled fibroblast activation protein inhibitor (FAPI) imaging is an effective and reliable technique for detecting both myocardial fibrosis and activated CFs in arterial plaques. Preliminary data suggest that FAPI imaging can characterize plaque composition and assess the extent of myocardial fibrosis in various cardiovascular conditions. However, its potential to predict the ease of CTO recanalization and subsequent clinical outcomes remains to be fully explored.\n\nThe aim of this prospective cohort study is to evaluate the predictive value of FAPI imaging in patients with at least one untreated CTO. All enrolled patients will undergo baseline assessments prior to intervention, including blood tests, clinical evaluations, and imaging studies. These imaging studies will include myocardial FDG\u002Fperfusion imaging, FAPI imaging, and resting perfusion imaging. In selected patients, additional evaluations such as stress myocardial perfusion imaging, magnetic resonance imaging (MRI), and echocardiography will also be performed.\n\nFor patients undergoing percutaneous coronary intervention (PCI), follow-up assessments will occur at 6 and 12 months. At the 6-month mark, improvements in left ventricular (LV) wall motion will be assessed using resting perfusion imaging. At 12 months, coronary angiography (CAG) will be performed on all patients to evaluate recanalization outcomes. Additionally, myocardial perfusion imaging, magnetic resonance imaging (MRI), and echocardiography may be selectively used to evaluate patients during the 12-month follow-up.\n\n1. To evaluate the ability of FAPI imaging in predicting the difficulty of CTO recanalization.\n2. To investigate the role of myocardial FAPI imaging in predicting the improvement of LV wall motion at 6 months, assessed using follow-up single-photon emission computed tomography (SPECT).\n\nBy comparing FAPI imaging with conventional prognostic assessment methods, this study aims to clarify the utility of FAPI imaging in both predicting the recanalization complexity and in assessing long-term clinical outcomes in CTO patients.",[27],[147,175,176,177,178],"Fibroblast activation protein inhibitor","Percutaneous coronary intervention","Imaging","Prognosis","2024-10-22",{"date":181,"type":38},"2024-10-24",{"date":183,"type":38},"2024-09-10",{"date":185,"type":20},"2026-08-31",{"name":161,"class":45},2,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":58,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100563018","feasibility-of-a-cardiac-rehabilitation-program-for-cto-patients-before-pci-treatment-100563018","NCT06610708","Feasibility of a Cardiac Rehabilitation Program for CTO Patients Before PCI Treatment","Pre-Intervention Rehabilitation to Optimize Patient Selection for Chronic Total Occlusion Percutaneous Coronary Interventions (PREHAB-CTO Study)","PREHAB-CTO","Inclusion Criteria:\n\n1. The presence of a chronic total occlusion in at least one major coronary artery (diameter ≥ 2.5mm).\n2. Patients who have an indication for percutaneous coronary intervention of a CTO, which includes the presence of:\n\n   1. Angina or anginal-equivalent symptoms and\n   2. Ischemia or viability in the CTO territory\n3. Patient aged ≥18 years of age.\n\nExclusion Criteria:\n\n1. Inability or refusal to participate in the study's cardiac rehabilitation program.\n2. Participation in CR program in the last 1 year.\n3. Life expectancy of \\< 12 months due to non-cardiovascular comorbidities.\n4. Anatomy deemed unsuitable for CTO PCI.\n5. Severe left main disease (angiographic stenosis ≥50%; fractional flow reserve ≤0.80; minimal lumen area \\<6mm2).\n6. Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the study period.\n7. Pregnancy.\n8. Acute coronary syndrome within two months.\n9. Canadian Cardiovascular Society Class ≥III angina of recent onset.\n10. Angina of any class with a rapidly accelerating pattern.\n11. Cardiac transplant recipient.\n12. Inability to understand the questionnaires used in the study.\n13. Patients unable to provide consent for the study.",{"count":197,"type":20},70,[60],"The goal of this clinical trial is to evaluate the feasibility of a cardiac pre-hab program for patients with blocked arteries (CTO) who are referred for PCI treatment. The main questions it aims to answer are:\n\nCan the pre-hab program improve patients\\' functional capacity before PCI? Does the pre-hab program impact the need for PCI based on improvements in patients\\' health?\n\nParticipants will:\n\nUndergo an initial assessment including a physical exam, medication history, quality of life questionnaires, and blood work.\n\nComplete a 6-month cardiac rehabilitation program. Have repeat assessments to evaluate improvements and determine if PCI is still needed.\n\nIf PCI is performed, be assessed again one month later for functional capacity improvements.\n\nIf PCI is not needed after 6 months, participants will be followed virtually for an additional 5 months.",[27],[118,202,203,204,205],"Chronic Total Occlusion","Prehabilitation","Prehab","PCI","2024-09-23",{"date":208,"type":38},"2024-09-24",{"date":210,"type":20},"2024-10",{"date":212,"type":20},"2026-10",{"name":214,"class":45},"Luiz Ybarra"]